儿童幼年特发性关节炎与非感染性葡萄膜炎患者抗阿达木单抗抗体研究
这项单中心回顾性观察研究纳入390例接受阿达木单抗治疗的儿童和年轻人,其中112例检测了抗阿达木单抗抗体(AAA)。AAA阳性率为41.0%,且与药物谷浓度不足及停药相关;未联用改善病情抗风湿药(DMARD)者AAA阳性率更高,抗体滴度短期波动提示单次阳性未必代表治疗失败。
要点
- AAA阳性率41.0%,亚治疗药物水平者均为阳性。
- 未联用DMARD者AAA阳性率52.4%,高于联用全剂量甲氨蝶呤者的21.1%。
- AAA阳性者停药比例53.1%,显著高于阴性者的15.2%。
核心结论
- 儿童JIA和/或NIU患者中抗阿达木单抗抗体发生率高,多数在疾病 flare 时检测。
- AAA阳性与亚治疗药物水平和停药相关,尤其在不联用全剂量甲氨蝶呤时。
- 抗体滴度短期波动提示单次阳性结果未必可靠指示治疗失败。
研究设计与样本
- 单中心回顾性观察研究,英国三级儿科风湿病专科服务。
- 纳入2015年1月至2024年1月期间接受阿达木单抗并检测AAA的儿童和年轻人。
- 共390例接受阿达木单抗治疗,其中112例检测AAA,共156次检测。
主要发现
- AAA阳性率41.0%(阈值>10 mg/L)。
- 所有药物水平亚治疗(<3 mg/L)者均为AAA阳性。
- 未联用DMARD者AAA阳性率52.4%,联用全剂量甲氨蝶呤者21.1%(OR 4.12, p=0.002)。
- AAA阳性者停药比例53.1%,AAA阴性者15.2%(OR 6.3, p<0.0001)。
- 连续检测显示AAA水平波动,使用皮质激素后可见下降。
关键数值与推荐
- AAA阳性定义为>10 mg/L。
- 亚治疗药物水平定义为<3 mg/L。
- 未联用DMARD者AAA阳性率52.4%,联用全剂量甲氨蝶呤者21.1%(OR 4.12, p=0.002)。
- AAA阳性者停药比例53.1%,阴性者15.2%(OR 6.3, p<0.0001)。
临床怎么用
- 对接受阿达木单抗的JIA/NIU患儿,尤其疾病 flare 时,应考虑检测AAA和药物水平。
- AAA阳性且药物水平亚治疗时,需评估联用全剂量甲氨蝶呤或调整治疗。
- 单次AAA阳性不宜直接判定治疗失败,可结合连续检测和临床情况综合判断。
局限性
- 单中心回顾性观察设计,可能存在选择偏倚。
- 仅112/390例接受了AAA检测,检测人群可能富集了疾病 flare 者。
- 原文未报告检测时机、随访时长及混杂因素调整等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adalimumab is an effective first-line biologic therapy used to treat children and young people (CYP) with juvenile idiopathic arthritis (JIA) and non-infectious uveitis (NIU). However, the development of neutralising antibodies may compromise adalimumab's efficacy. This study investigated the incidence and clinical relevance of anti-adalimumab antibody (AAA) development in CYP treated with adalimumab for JIA and/or NIU. METHODS: A retrospective observational study was conducted within a specialist paediatric rheumatology service at a tertiary UK centre. CYPs receiving adalimumab between January 2015 and January 2024 who were tested for AAAs were included. Outcome measures included AAA positivity rate, serum drug levels, concurrent disease-modifying anti-rheumatic drug (DMARD) use, timing of antibody development and patient outcomes following AAA results. RESULTS: Among 390 CYP treated with adalimumab, 112 were tested for AAAs (156 total tests). Overall, 41.0% were AAA positive (>10 mg/L). All CYP with sub-therapeutic drug levels (<3 mg/L) were AAA positive. AAA positivity was higher in CYP not receiving concurrent DMARDs (52.4%) compared with those receiving full-dose methotrexate (21.1%) (OR 4.12, p=0.002). Among AAA-positive patients, 53.1% discontinued adalimumab treatment versus 15.2% of AAA-negative patients (OR 6.3, p<0.0001). Serial testing revealed fluctuating AAA levels, including reductions following corticosteroid use. CONCLUSIONS: High AAA incidence was observed in CYP with JIA and NIU, with most tested during disease flare. AAA positivity correlated with sub-therapeutic drug levels and treatment discontinuation, particularly in the absence of concurrent full-dose methotrexate. Short-term variability in antibody titres suggests that a single positive result may not reliably indicate treatment failure.
引用
- Wilson CR, Somerville SR, Hawley DP, et al. Single-centre observational study of anti-adalimumab antibody development in children and young people treated for juvenile idiopathic arthritis and/or non-infectious uveitis. Br J Ophthalmol. 2026. PMID: 41856771. doi:10.1136/bjo-2025-328938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。